Q-omics provides the consensus-scored IL18 profile across patient tissues and cancer cell-line models. IL18 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, IL18 is differentially expressed in 11, with the highest sampling consensus in THCA. Additionally, IL18 protein abundance shows 22,209 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight SKCM, THCA, and GBM as cancer lineages where IL18 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for IL18 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes IL18 survival associations across molecular data types. IL18 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (2) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible IL18 RNA expression–survival associations across cancer types. High IL18 expression shows unfavorable associations in PAAD, LGG, ACC and UVM, but favorable associations in SKCM and DLBC. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for IL18 RNA expression.
This table summarizes IL18 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 3. The strongest signals are observed in THCA for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for IL18. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. IL18 shows lower tumor expression in LUSC and higher tumor expression in THCA, KIRC, KIRP, KICH and BRCA. The THCA box plot shows higher IL18 RNA expression in tumor versus normal tissue (log2 FC = +2.127, t-test p < 0.001).
This table shows molecular features associated with IL18 in patient tissues and cancer cell lines. In patient samples, IL18 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, IL18 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in BREAST and BLOOD_Leukemia.
